Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2020
Use of patient preference studies in HTA decision making: a NICE perspective
16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...
Posted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...
Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...
Posted by Michael Wonder on 15 Jan 2020
NICE rejects Keytruda, asks for more information
15 January 2020 - NICE has published a new draft guidance not recommending MSD’s cancer blockbuster Keytruda (pembrolizumab) for untreated ...
Posted by Michael Wonder on 13 Jan 2020
Novartis strikes deal with UK to provide cholesterol drug to high-risk patients
13 January 2020 - Pharmaceutical giant Novartis reached a deal with the U.K. to provide its late-stage cholesterol drug, inclisiran, to ...
Posted by Michael Wonder on 12 Jan 2020
The Tories must learn from the Orkambi victory and keep drug-pricing off the table
12 January 2020 - To match its rhetoric on the NHS, the government has to legally commit to preventing drug-pricing being ...
Posted by Michael Wonder on 07 Jan 2020
As Brexit nears, fears of an NHS sell-out resurface
6 January 2020 - In the lead up to December’s general election in Britain one of the main campaign issues ...
Posted by Michael Wonder on 04 Jan 2020
NICE refuses Akcea’s Waylivra
3 January 2020 - NICE has issued an Evaluation Consultation Document, refusing Waylivra (volanesorsen) as a treatment for familial chylomicronaemia ...
Posted by Michael Wonder on 03 Jan 2020
Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff
2 January 2020 - Paper looks at how histology-independent cancer drugs might be appraised. ...
Posted by Michael Wonder on 02 Jan 2020
Tecentriq hit with draft NICE rejection
2 December 2020 - NICE has issued a new draft guidance, advising against the use of Roche's Tecentriq (atezolizumab) for ...
Posted by Michael Wonder on 16 Dec 2019
NICE u-turn backs NHS use of Veltassa
16 December 2019 - The National Institute for Health and Care Excellence has given its stamp of approval for NHS ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 10 Dec 2019
Biotech companies defend prices of one-off gene therapy
9 December 2019 - Latest treatments with price tags as high as $2 million require new financing models. ...